John Fanikos Shares Greg Piazza’s Presentation On The Results of The HI-Pro Trial
John Fanikos, Director of Strategic Initiatives at North American Thrombosis Forum, shared on LinkedIn:
”The best part of my pharmacist career was spending time with the Thrombosis Research Group.
Dr. Greg Piazza presented the results of the HI-Pro Trial at the European Society Meeting over the Labor Day weekend in Madrid, Spain.
There are often reasons (surgery, infection, injury) patients developed blood clots (deep vein thrombosis and pulmonary embolism) in their legs and lungs.
These events were called “provoked” and treated with medicines (anticoagulants) for 3-6 months.
Dr. Piazza’s research suggests treating longer, and with a lower dose, may prevent repeat events and be better for patients.
Kudos to the research group. Kudos to the Investigational Drug Service Pharmacy (IDS) that delivered the drugs by foot, by FedEx, and by UPS in the peri-pandemic period to keep patients on their medications.
I was honored to be included.”
Stay updated on the latest news in the field of thrombosis with Hemostasis Today.
-
Jul 9, 2026, 11:54Deepak Pradhan։ Can Withaferin-A Help Combat Drug-Resistant Malaria?
-
Jul 9, 2026, 11:26Peter Zhang: Is Canada Ready for the Gene Therapy Era?
-
Jul 9, 2026, 09:35Pradeebha Muthukumar: Do You Know the Signs of Anemia?
-
Jul 9, 2026, 09:24Maryam Majid: Machine Learning for Anemia Risk Prediction
-
Jul 9, 2026, 08:46Jordan Agay: Folate Deficiency in Patients Receiving PARP Inhibitors
-
Jul 9, 2026, 08:29Laura Katz: Is Human Lactoferrin Better Than Bovine Lactoferrin?
-
Jul 9, 2026, 08:17Anziya Sabeer: AI-Driven Non-Invasive Anemia Detection
-
Jul 9, 2026, 07:37Variable Mechanisms of ADAMTS13 Inhibition by Autoantibodies in iTTP – JTH
-
Jul 9, 2026, 07:31DHR-Sponsored Training Programme at ICMR-CRMCH Week 2 – Day 4 – ICMR-NIRBID